Technical Analysis for ABUS - Arbutus Biopharma Corporation

Grade Last Price % Change Price Change
grade F 0.9272 -0.15% 0.00
ABUS closed down 0.15 percent on Friday, October 18, 2019, on 34 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Nov 5

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Flat
See historical ABUS trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -0.15%
Oversold Stochastic Weakness -0.15%
1,2,3 Retracement Bearish Bearish Swing Setup -0.30%
180 Bearish Setup Bearish Swing Setup -0.30%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.30%

Older signals for ABUS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Arbutus Biopharma Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics, and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. The company's products for Hepatitis B virus (HBV) comprise TKM-HBV, a RNAi therapeutic in Phase I clinical trial; OCB-030, a cyclophilin inhibitor drug candidate; CYT-003, a TLR9 agonist; capsid assembly inhibitors for use as oral therapeutics; surface antigen secretion inhibitors; STING agonists, a stimulator of interferon genes research program; cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; and cccDNA epigenetic modifiers, a research program to inhibit the formation of new virus and subviral particles from cccDNA. Its products also include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-Ebola, an anti-ebola viral therapeutic in Phase I clinical trial; and TKM-Ebola-Guinea, an anti-ebola RNAi therapeutic in Phase 2 trial. In addition, the company develops TKM-Marburg to treat Marburg infections; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02, a therapeutic targeting transthyretin amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in August 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Biopharmaceutical Medical Specialties Infectious Diseases Hepatitis B Hepatocellular Carcinoma Hypercholesterolemia PLK1 Sexually Transmitted Diseases And Infections Zoonoses Arbutus Biopharma Liver Cancer Primary Hyperoxaluria Transthyretin Amyloidosis Tropical Diseases
Is ABUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 5.66
52 Week Low 0.83
Average Volume 268,537
200-Day Moving Average 2.5619
50-Day Moving Average 1.3936
20-Day Moving Average 1.1903
10-Day Moving Average 0.9256
Average True Range 0.1133
ADX 38.57
+DI 9.5644
-DI 27.4432
Chandelier Exit (Long, 3 ATRs ) 1.3601
Chandelier Exit (Short, 3 ATRs ) 1.1699
Upper Bollinger Band 1.7672
Lower Bollinger Band 0.6134
Percent B (%b) 0.27
BandWidth 96.933546
MACD Line -0.1712
MACD Signal Line -0.1568
MACD Histogram -0.0144
Fundamentals Value
Market Cap 51.02 Million
Num Shares 55 Million
EPS -5.07
Price-to-Earnings (P/E) Ratio -0.18
Price-to-Sales 164.81
Price-to-Book 1.74
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.02
Resistance 3 (R3) 1.02 0.99 1.00
Resistance 2 (R2) 0.99 0.97 0.99 1.00
Resistance 1 (R1) 0.96 0.95 0.94 0.96 0.99
Pivot Point 0.93 0.93 0.92 0.93 0.93
Support 1 (S1) 0.90 0.91 0.88 0.90 0.86
Support 2 (S2) 0.87 0.89 0.87 0.86
Support 3 (S3) 0.84 0.87 0.85
Support 4 (S4) 0.84